Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
Leap Therapeutics, Inc. (NASDAQ:LPTX) announced the expiration of BeiGene's option under their Exclusive Option and License Agreement for DKN-01, its anti-DKK1 monoclonal antibody, in certain Asian territories. Despite this, both companies will continue their collaboration on the DisTinGuish trial, which studies DKN-01 in combination with BeiGene's tislelizumab and chemotherapy for first-line gastric cancer. The trial aims for 160 patient enrollment completion by late 2023. Leap's cash runway extends to mid-2025, facilitating further clinical studies and the development of its Claudin18.2 programs for GI cancers.
- Continued collaboration with BeiGene on the DisTinGuish trial for DKN-01, indicating ongoing clinical progress.
- Cash runway enhanced into mid-2025, supporting continued development of clinical programs.
- Expiration of BeiGene's option for DKN-01 in Asia may limit market opportunities in those regions.
DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration
"We look forward to continuing to collaborate with BeiGene to execute on our first randomized controlled trial for DKN-01 in first-line gastric cancer patients," said
About
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the continuation over time of our clinical collaboration with BeiGene on the ongoing Part C of the DisTinGuish trial, with BeiGene continuing to supply tislelizumab; the enhancement of our cash runway into mid-2025; our future development plans in connection with our newly-acquired Claudin18.2 programs; the potential, safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including the anticipated timing for enrollment of clinical trials and release of clinical trial data and outcomes of such trials; the ability to enter into a new strategic partnership for DKN-01 or any of Leap's other programs; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully execute its clinical trials and the cost of such clinical trials; (ii) Leap's ability to successfully enter into new strategic partnerships for DKN-01 or any of its other programs; (iii) whether any Leap clinical trials and products will receive approval from the
CONTACT:
President & Chief Executive Officer
617-714-0360
donsi@leaptx.com
Investor Relations
212-600-1902
leap@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-provides-update-on-beigene-option-agreement-for-dkn-01-301774367.html
SOURCE
FAQ
What is the latest update on Leap Therapeutics and BeiGene's collaboration for DKN-01?
When is the enrollment completion date for the DisTinGuish trial involving DKN-01?
How has Leap Therapeutics extended its financial runway?